Congreso EADV 2024: Un nuevo estudio demuestra que la semaglutida mejora los resultados de los pacientes obesos con afecciones cutáneas comunes Un estudio pionero, presentado hoy en el Congreso EADV 2024, demuestra el potencial significativo de la semaglutida en el tratamiento de la…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.